These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses. Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440 [TBL] [Abstract][Full Text] [Related]
43. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis. Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903 [TBL] [Abstract][Full Text] [Related]
44. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α- Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673 [TBL] [Abstract][Full Text] [Related]
45. Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry. Kubaski F; Mason RW; Nakatomi A; Shintaku H; Xie L; van Vlies NN; Church H; Giugliani R; Kobayashi H; Yamaguchi S; Suzuki Y; Orii T; Fukao T; Montaño AM; Tomatsu S J Inherit Metab Dis; 2017 Jan; 40(1):151-158. PubMed ID: 27718145 [TBL] [Abstract][Full Text] [Related]
46. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925 [TBL] [Abstract][Full Text] [Related]
47. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Gliddon BL; Hopwood JJ Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919 [TBL] [Abstract][Full Text] [Related]
48. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A. Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820 [TBL] [Abstract][Full Text] [Related]
49. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease. Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477 [TBL] [Abstract][Full Text] [Related]
50. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Yogalingam G; Hopwood JJ Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611 [TBL] [Abstract][Full Text] [Related]
51. Development and validation of an LC-MS/MS Method for the quantitation of heparan sulfate in human urine. Wang K; Li M; Xiao Y; Ma M; Hu W; Liang T; Lin ZJ Biomed Chromatogr; 2018 Oct; 32(10):e4294. PubMed ID: 29797526 [TBL] [Abstract][Full Text] [Related]
53. Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy. Downs-Kelly E; Jones MZ; Alroy J; Cavanagh KT; King B; Lucas RE; Baker JC; Kraemer SA; Hopwood JJ J Mol Neurosci; 2000 Dec; 15(3):251-62. PubMed ID: 11303788 [TBL] [Abstract][Full Text] [Related]
54. Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice. McCarty DM; DiRosario J; Gulaid K; Killedar S; Oosterhof A; van Kuppevelt TH; Martin PT; Fu H Metab Brain Dis; 2011 Mar; 26(1):9-19. PubMed ID: 21225451 [TBL] [Abstract][Full Text] [Related]
55. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III. de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433 [TBL] [Abstract][Full Text] [Related]
56. The combined use of enzyme activity and metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type I. Polo G; Gueraldi D; Giuliani A; Rubert L; Cazzorla C; Salviati L; Marzollo A; Biffi A; Burlina AP; Burlina AB Clin Chem Lab Med; 2020 Nov; 58(12):2063-2072. PubMed ID: 32432561 [TBL] [Abstract][Full Text] [Related]
57. Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice. Dwyer CA; Scudder SL; Lin Y; Dozier LE; Phan D; Allen NJ; Patrick GN; Esko JD Sci Rep; 2017 Apr; 7():46576. PubMed ID: 28418018 [TBL] [Abstract][Full Text] [Related]
58. Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. Marshall NR; Hassiotis S; King B; Rozaklis T; Trim PJ; Duplock SK; Winner LK; Beard H; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM Exp Neurol; 2015 Jan; 263():79-90. PubMed ID: 25246230 [TBL] [Abstract][Full Text] [Related]
59. Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. Zhang H; Young SP; Auray-Blais C; Orchard PJ; Tolar J; Millington DS Clin Chem; 2011 Jul; 57(7):1005-12. PubMed ID: 21576268 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]